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Conclusions: This study shows that Tregs represent an impor-
tant fraction of HIV-specific T cells. Tregs impact the frequency
and the capability of effector cells to control viral replication.
Thus the ability to measure the inducibility of Tregs and/or to
modulate those responses prior to vaccination is important for
more efficient strategies in future vaccines.
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Background: Unprotected sexual intercourse is the most com-
monmode of HIV-1 transmission being semen the most important
vector for this infection. Dendritic cells (DCs) are abundantly
located on mucosal surfaces and play different roles during HIV
infection: promote HIV spread by boosting CD4+ T cell infection
and activate the HIV specific adaptive immune response. As se-
men has been shown to promote immune tolerance in different
models, we hypothesize that components present in plasma
seminal (SP) might modulate DC function promoting a tolero-
genic immune response. To test this, we study the ability of
complete SP to modulate DC function and the ability of these cells
to induce CD25+ /FOXP3+ regulatory T cells.
Methods: SP was obtained from healthy donors. Monocyte de-
rived DCs were cultured during 24 hs with SP samples (diluted 1/
100) in the absence or presence of LPS (10ng/ml). DC phenotype
was studied by flow cytometry. Cytokine secretion was measured
in culture supernatants by ELISA. After SP treatment, DCs were
cultured with allogeneic CD4+ T cells and the induction of
CD25+ /FOXP3+ T cells was analyzed by flow cytometry.
Results: We found that SP inhibited IL-12, IL-6, TNF-alpha and
IL-1, but not IL-10 production by LPS stimulated DCs (percent of
inhibition respect to LPS alone: 81.2+ /-11.07% p<0.0001 for
IL-12, 43.45+ /-2.87% p< 0.001 for IL-6, 69.8+ /-17.31%
p< 0.001 for TNF-alpha, 37.5+ /-13.15% p<0.05 for IL-1,
6.1+ /-15.6%p=0.6 for IL-10). SP also boosted the ability of LPS
stimulated DCs to induce CD25+ /FOXP3+ T cells (PS+LPS=
20,4% vs LPS alone= 6%, p< 0,05). We observed no changes on
the expression of HLA-DR, CD80, CD86, CD83, CD40 and CD1a
on immature or LPS-maturated DCs after incubation with SP.
Conclusions: SP modulates DC function, inhibiting the secre-
tion of pro-inflammatory cytokines and favoring the induction of
CD25+ /FOXP3 + T cells. In this way, we speculate that SP
might modulate the adaptive immune response against sexual
transmitted pathogens.
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Background: Virus-specific CD8 T cell responses to epitopes
restricted by HLA-B*35:01 are generally believed to be inef-
fective in mediating in vivo control of HIV infection. We report a
case of a patient homozygous for HLA-B*35:01 who showed
successful viral control after vaccination with MVA-B vaccine
combined with a drug to reactivate HIV-1 replication (disulfi-
ram), and who subsequently underwent an analytical treatment
interruption (ATI).
Methods: Therapeutic vaccination consisted of 3 intramuscular
injections of MVA-B at 0,4,16 weeks and a 4th dose followed by
2 months of disulfiram. cART was discontinued 8 weeks after
last vaccination. IFN-c ELISPOT was used to assess immuno-
genicity and proviral reservoir was determined over time. Viral
rebound dynamics were assessed during ATI.
Results: The patient had a past history of high viral load set
point (362,000 copies/ml) and cART was initiated during
chronic infection. After ATI the patient remained with low level
viral load< 200 copies/ml for> 24 weeks without showing a
significant decay in CD4 T-cell counts. At baseline, the patient
showed a broad (19 different specificities) and strong (9,189
SFC/106PBMC) T cell response, which increased to 14,470
SFC/106PBMC after three vaccinations. Responses to three
novel T-cell epitopes present in the vaccine insert (Nef A*03-
QK10, Gag A*03-RK9 and Pol B*35-VY10) were induced upon
3 vaccination. A dominant HLA-B*35:01 restricted response to
the Gag-p24 B*35-PY9 epitope (PPIPVGDIY) of 3,330 SFC/
106PBMC was detected before ATI. No changes in proviral
reservoir or viral expression (mRNA) were observed in CD4+
T-cells after disulfiram treatment.
Conclusions: The expansion of a dominant response towards the
HLA-B*35- restricted Gag RY9 epitope could potentially explain
the observed viral control on this subject suggesting that certain
HLA-B*35:01 restricted responses may have the potential to
significantly contribute to viral control, providing important
guidance for vaccine immunogen design covering non-beneficial
HLA alleles.
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Background: The limited success of HIV vaccine candidates to
date highlights our need to better characterize protective cell-
mediated immunity (CMI). HIV-infected subjects that experi-
ence slower progression to AIDS, provide a valuable model for
the study of CMI responses that may be capable of controlling
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